TFS Capital’s Haemonetics HAE Stock Holding History

TFS Capital’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-30,385	Closed	-$1.23M	–	681
2017 Q1	$1.23M	Buy	+30,385	New	+$1.19M	0.4%	37
2016 Q4	–	Sell	-6,415	Closed	-$232K	–	797
2016 Q3	$232K	Sell	6,415 -29,042	-82%	-$997K	0.06%	504
2016 Q2	$1.03M	Buy	+35,457	New	+$1.07M	0.19%	172
2015 Q4	–	Sell	-39,048	Closed	-$1.26M	–	800
2015 Q3	$1.26M	Buy	39,048 +14,061	+56%	+$529K	0.12%	279
2015 Q2	$1.03M	Buy	+24,987	New	+$1.05M	0.1%	325
2014 Q3	–	Sell	-90,988	Closed	-$3.21M	–	1101
2014 Q2	$3.21M	Buy	90,988 +19,208	+27%	+$642K	0.25%	94
2014 Q1	$2.34M	Buy	+71,780	New	+$2.74M	0.15%	183
2013 Q4	–	Sell	-7,118	Closed	-$284K	–	1534
2013 Q3	$284K	Sell	7,118 -859	-11%	-$36K	0.01%	1122
2013 Q2	$330K	Buy	+7,977	New	+$323K	0.01%	1097

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TFS Capital's HAE Position: Q2 2017 in Review

TFS Capital sold out of Haemonetics (HAE) in Q2 2017, closing a stake of 30,385 shares — an estimated $1.23M sold.

TFS Capital first reported a position in HAE in Q2 2013 and held it in 9 quarters. The position peaked at $3.21M in Q2 2014. 197 funds tracked by Wall St. Rank hold HAE as of Q2 2017.

TFS Capital reported no remaining Haemonetics position as of Q2 2017 after selling out during the quarter.
TFS Capital sold 30,385 Haemonetics shares in Q2 2017, an estimated $1.23M.
TFS Capital first reported a position in Haemonetics in Q2 2013 and held it in 9 quarters.
TFS Capital's Haemonetics position peaked at $3.21M in Q2 2014.
197 funds tracked by Wall St. Rank held Haemonetics as of Q2 2017.

Based on TFS Capital's 13F filing for Q2 2017, filed 11 Aug 2017.